Financial Performance - Core EPS increased by 16% to $1.16, compared to $1.00 in 3Q24[18, 33] - Core earnings increased by 10% to $2,035 million, compared to $1,828 million in 3Q24[30, 32] - Adjusted book value per share increased by 12% to $38.22, compared to $34.27 in 3Q24[18, 48] - New business CSM grew by 25% to $966 million, compared to $759 million in 3Q24[16, 29] - New business value increased by 11% to $906 million, compared to $806 million in 3Q24[16, 29] Business Segment Performance - Asia core earnings grew by 29% to $550 million (US dollars), driven by strong growth momentum[25, 36] - Global WAM core earnings increased by 9% to $525 million (Canadian dollars), supported by AUMA growth and expense management[39] - Canada APE sales increased by 9% to $374 million[42] Capital Management - The company's LICAT ratio was 138%[18, 53] - The financial leverage ratio decreased to 22.7%[18, 53]

Financial Performance & Outlook - Alvotech revised its FY2025 revenue outlook to $570-600 million, compared to the previous $600-700 million[20, 25, 72] - Adjusted EBITDA for FY2025 is revised to $130-150 million, down from the earlier $200-280 million[20, 25, 72] - Total revenues for 9M25 reached $420 million, a 24% increase year-over-year compared to 9M24[53, 54, 58] - Licensing revenues are expected to contribute $250-300 million annually until 2030[25] - The company's cash balance as of September 30, 2025, was $43 million[53, 54, 61] Product Pipeline & Approvals - The FDA issued a Complete Response Letter (CRL) for AVT05 (biosimilar to Simponi®) due to unresolved issues identified during a July inspection[20, 21, 22] - The Reykjavik manufacturing facility remains FDA approved for commercialized products like bHumira and bStelara[20, 22] - Approvals and/or positive CHMP opinions have been received for AVT06 (bEylea), AVT05 (bSimponi), and AVT03 (bProlia/Xgeva) by EMA and Japan's PMDA[20, 22, 33] - Alvotech expects to be among the first to launch a bSimponi in the EU, UK, and Japan[22, 33] Market Performance - Alvotech's biosimilar to Humira (AVT02) holds the second-largest market share of Humira biosimilars in the U S[28] - In Europe, Alvotech's Humira biosimilar volumes continue to grow, with Hukyndra holding a top position in several EU10 markets and experiencing 12% QoQ growth for the last four consecutive quarters[28] - Alvotech is securing formulary coverage for its Stelara biosimilar (AVT04) in the U S, and holds a leading position in Europe with approximately 10% overall share of the total Stelara market[20, 28]

Investor Relations Highlights 3Q25 Financial Indicators | | | | | | | R$ million | | --- | --- | --- | --- | --- | --- | --- | | Indicators Highlights | 3Q25 | 3Q24 | ∆% | 9M25 | 9M24 | ∆% | | Ebitda (R$ million) | 1,358.7 1,526.7 | | | -11.0 4,678.0 4,230.8 | | 10.6 | | Recurring Ebitda | 1,337.4 1,240.3 | | | 7.8 4,175.6 3,852.1 | | 8.4 | | Net Profit (R$ million) | 383.1 1,217.1 | | | -68.5 1,621.3 2,224.2 | | -27.1 | | Recuring Net Profit (R$ million) | 369.0 1,021.2 | | | -36.5 1,404.1 1,346.1 | | 4.3 ...

HPC/AI Infrastructure and Strategy - Bitfarms has a 1.9 GW power infrastructure asset portfolio in high-demand HPC/AI regions in North America, located in cool climates for improved efficiency[24] - The company is developing 18 MW of HPC/AI infrastructure at its Washington site for Nvidia Blackwell in 2026, with a secured supply chain for $128 million[26, 28] - Panther Creek in Eastern Pennsylvania is planned as a flagship HPC/AI campus with over 410 MW of power and 316 acres of land, with Phase 1 (50 MW) expected in H1 2027 and Phase 2 (300 MW) in H2 2027[33, 34] - Bitfarms has 170 MW of hydropower operating across multiple sites in Quebec, with potential to convert BTC mining infrastructure to HPC/AI[38] - Scrubgrass is a potential gigacampus site with 1.3 GW capacity and 650 acres, offering proximity to Pittsburgh and Cleveland[39, 40] Financial Performance and Capitalization - Bitfarms reported ~$8 million in monthly free cash flow from BTC mining operations in Q3 2025[49] - Q3 2025 revenue was $69 million, a 11% increase Q/Q and a 900% increase Y/Y[51] - Adjusted EBITDA for Q3 2025 was $20 million, a 122% increase Q/Q[51] - The company has over $1 billion in cash and Bitcoin on hand, with remaining funds available from the Macquarie facility[55] Strategic Initiatives - Bitfarms is undergoing a U S pivot, with the majority of planned MW development based in the U S , a new NYC office, and a transition to U S GAAP accounting, aiming for U S redomicile in 2026[42] - The company is evaluating a cloud monetization strategy for its Washington site to replace BTC mining cash flows[42]

Corporate Overview - As of September 30, 2025, Aldeyra's cash, cash equivalents, and marketable securities totaled $75.3 million, expected to fund the company into the second half of 2027[7] - Aldeyra is developing reproxalap for dry eye disease and allergic conjunctivitis, ADX-248 for obesity/hypertriglyceridemia and CNS/Neuroinflammatory Disease, ADX-246 for Dry Age-Related Macular Degeneration/Geographic Atrophy, and ADX-2191 for Primary Vitreoretinal Lymphoma and Retinitis Pigmentosa[6] RASP Modulation and ADX-629 - Reactive Aldehyde Species (RASP) modulation represents a novel pharmacology that may allow for control of protein systems, without turning any single protein on or off[16] - ADX-629, a first-generation RASP modulator, demonstrated activity in Phase 2 clinical trials, including statistically significant changes in lipid profiles (HDL, LDL/HDL ratio, FFA) and reduction of C-Reactive Protein in Alcohol-Associated Hepatitis[21, 29, 35] ADX-246 and ADX-248 - ADX-246, by binding the RASP retinaldehyde, potentially represents a new intravitreally administered therapy for the treatment of Dry Age-Related Macular Degeneration (Dry AMD), showing a reduction in toxic retinaldehyde metabolite A2E in an Abcr Knockout Mouse model[41, 42] - ADX-248, by binding HNE, a pro-inflammatory RASP, potentially represents a new orally administered therapy for the treatment of immune-mediated disease, demonstrating cytokine reduction in LPS-Challenged Mice and improved Epidermal Erosion Score in an Oxazolone Mouse Model of Atopic Dermatitis[44, 45] - ADX-248 significantly improved Rotarod Performance and Grip Strength in the Mouse MPTP Parkinson's Disease Model, as well as Wire Hang Time in the Rat 6-OHDA Parkinson's Disease Model[61, 69] - ADX-248 significantly improved Grip Strength and Rotarod Performance in the Mouse SOD1-G93A Amyotrophic Lateral Sclerosis Disease Model[72] Reproxalap - Reproxalap represents a novel potential therapeutic approach in Dry Eye Disease with rapid activity observed in clinical trials, with a PDUFA Target Action Date of December 16, 2025[85, 89] - The Phase 3 Dry Eye Chamber Trial achieved the primary endpoint of ocular discomfort (P=0.002 for Prespecified Analysis and P=0.004 for Post-Hoc Treatment Chamber Analysis)[87, 88] - Aldeyra has entered into an exclusive option agreement with AbbVie Inc for license to develop and commercialize Reproxalap, including a potential upfront payment of $100 million less option fees, a $100 million milestone payment upon U S FDA approval in dry eye disease, and $200 million in additional regulatory and commercial milestones[95, 97]

Business Highlights - The company's customer numbers increased by 156% year-over-year (YoY) and 24% quarter-over-quarter (QoQ)[8] - Annual Recurring Revenue (ARR) reached RMB 5370万 in September 2025, representing a YoY growth of over 160%[9] - EngageLab's customers span 52 countries and regions, with offices established in Hong Kong, Singapore, Malaysia, and Japan[12] - GPTBots.ai entered a strategic partnership with Vonosis Co, Ltd in Thailand to deliver localized AI solutions[15] - EngageLab upgraded its Marketing Automation functions with AI-powered capabilities to enhance marketing efficiency and user conversion rates[18] Financial Highlights - The company achieved GAAP net income for two consecutive quarters, a historic first[29, 33] - Q3 2025 recorded the highest quarterly revenue in EngageLab's history[29] - Net Dollar Retention (NDR) for Developer Services (Subscription) reached 104%, the highest level in history[29, 53] - Total revenue reached RMB 9090万, a 15% YoY increase and 1% QoQ increase[36] - Gross profit increased by 20% YoY and 7% QoQ, reaching RMB 6380万, the highest level in the past 15 quarters, with a gross margin of 702%[30, 46] - Deferred revenue reached RMB 16630万, a historic high[30, 50, 53]

Q3 2025 EARNINGS PRESENTATION November 13, 2025 Disclaimer This presentation (this "Presentation") has been prepared by Okeanis Eco Tankers Corp. ("OET or the "Company"). This Presentation does not constitute or form part of, and should not be construed as, an offer to sell or an invitation, solicitation, or inducement to purchase or subscribe for securities with respect to any transaction, nor shall it or any part of it form the basis of, or be relied on in connection with, any contract or commitment whats ...

• 1 Casella Waste Systems, Inc. Investor Presentation November 2025 Safe Harbor Statement Certain matters discussed in this presentation, including, but not limited to, the statements regarding our intentions, beliefs or current expectations concerning, among other things, our financial performance; financial condition; operations and services; prospects; growth; strategies; anticipated impacts from future or completed acquisitions; and guidance for fiscal year 2025, are "forward-looking statements" intende ...

La Guitarra Mine Operations & Expansion - Full commercial production at La Guitarra Mine commenced on January 1, 2025[13, 27] - Q3 2025 sales reached 153,583 silver equivalent ounces[13] - Q3 2025 revenues totaled $5.5 million[13] - Gross profit for Q3 2025 was $1.7 million[13, 47] - A C$19.5 million private placement closed in July 2025 to fund plant expansion[13, 40] - Expansion plans aim to increase capacity by +50% to 750-800 tonnes per day by Q2 2026 and +100% to 1,200-1,500 tonnes per day by Q3 2027[48, 49, 51] La Guitarra Resource Estimate - The 2023 resource update shows 272 million silver-equivalent Measured & Indicated ounces, a 373% increase[31] - Inferred resources are 202 million silver-equivalent ounces, a 204% increase[31] Tepic Project Exploration - Exploration at Tepic Project indicates a potential strike length of over 15 km[75, 76] - Historical ore shoots in the East District measure up to 750 meters in length and 1-4 meters in thickness[57] Financials & Share Structure - Current assets, including cash, were $16.9 million as of September 30, 2025[84, 93] - A $5 million loan from First Majestic Silver bears interest at 15% per annum[64, 71, 84]

DarioHealth Corp. The innovative, scalable platform for cost efficient, whole-body health November 2025 Forward-Looking Statement This presentation of DarioHealth Corp. ("Dario", the "Company", "we" and "our") and statements of our management or agents related thereto contain or may contain forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Statements which are not historical reflect our current expectations and projections about our future re ...